Here are four things to know about the deal.
1. Under the all-stock deal, Amneal shareholders will own 75 percent of the new company — named Amneal Pharmaceuticals — and Impax shareholders will own the other 25 percent.
2. Paul Bisaro, Impax’s president and CEO, will take over as CEO of the combined company.
3. The new company will boast a very diverse pipeline, featuring more than 300 products filed with the Food and Drug Administration or in active stages of development.
4. Impax and Amneal expect the deal to close in the first half of 2018.
More articles on supply chain:
This biohacker is creating a recipe book of medicines patients can make at home
6 drug, devicemakers in the headlines
Roche taps drug discovery firm to develop new antibiotic classes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.